This pathway has been subjected to several therapeutic trials utilizing IGF-blocking drugs to stop the progression of pancreatic cancer; but, there has been little success, which may be attributable to the complex nature of this signaling system. This evidence concerns the gene IGF1 and familial pancreatic carcinoma.